Solasia Pharma K.K. 4597.T Stock

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.